Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Gene therapy
- Ocugen to Present Pioneering Gene Therapy Data at Retinal Innovation Summit
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present findings from the OCU400 Phase 1/2 clinical trials at the upcoming Retinal Cell ...
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Nanoscope Therapeutics: Gene Therapy Improves Visual Acuity in Patients with Retinitis Pigmentosa
Gene therapy demonstrated clinically meaningful vision improvement in legally blind individuals. The therapy is capable of restoring vision even in advanced disease stages. The Latest A recent ...
- OSU researchers pioneer technique for delivering gene therapy to specific brain areas
Researchers say the procedure holds promise for a host of genetic neurological disorders, including Parkinson's, Alzheimer's, multiple system atrophy (ASA) and more.
- What Lies Ahead? Shaping the Future of Cell and Gene Therapy
Sponsored content brought to you by The launch of Revvity, Inc. in May 2023 signaled the rebranding of an 85-year-old company with a dedicated focus on the diagnostics and life sciences sector.
Go deeper with Google Headlines on:
Gene therapy
[google_news title=”” keyword=”gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Designer cytokine
- Cell Therapy Manufacturing: Time to Move Fast
The more quickly manufacturing and release obstructions can be cleared, the sooner lifesaving treatments can be administered.
- New blood test shows promise in early detection of ovarian cancer
A study reveals that glycoproteins in blood could be key biomarkers for early detection and staging of epithelial ovarian cancer, potentially allowing diagnosis through a simple blood test.
- Pregnancy cytokine levels impact fetal brain development and offspring behavior
image: The maternal hormone-like cytokine XCL1 acts interacts with specific receptors (green) on the surface of specialized fetal placenta cells (red). c’, c’’ show specialized fetal cells ...
- ‘Key Signs’ of Cytokine Release Syndrome to Know
For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...
- Researchers find pregnancy cytokine levels impact fetal brain development and offspring behavior
The study published online in Brain, Behavior, and Immunity on Feb 29, reported that cytokine XCL1 produced by maternal immune cells can function as a pregnancy hormone and is required for the ...
Go deeper with Google Headlines on:
Designer cytokine
[google_news title=”” keyword=”designer cytokine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]